AFLAC INC (AFL): what the price requires

At today's price, AFLAC INC (AFL) is priced for 14.1% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/AFL

Headline

FieldValue
TickerAFL
CompanyAFLAC INC
Current price$123.31/sh
CompositionAflac Japan 58% / Aflac U.S. 42%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed14.1%
Return on equity now12.4%
ROE gap+1.7pp
Price-to-book2.09x

Solve inputs: computed at a 8.8% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~2.1pp.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.90σ
cohort percentile (of 80 peers)56
sustained it ~10 years at this level63%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.15x3expensive
Earnings0.87x2justifies
Relative1.08x3expensive
Growth1.03x1expensive

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.3%); the inversion above states its own rate.

Per-Model Detail (n=9)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$107.261.15xyesTBVPS $58.20 × 1.84x (ROE (TTM) 15.5% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 4.68% allowance/loans → ×0.81, NPL 6.90% → ×0.92)
Relative ValuationRelative$113.851.08xyesP/E 11x (static sector reference · 2026-04), scenarios: 9.0x / 11.0x / 13.0x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$97.361.27xyesBV/sh $58.20, ROE (TTM) 15.5%, ke 9.3%
Two-Stage Excess ReturnAsset$124.370.99xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$120.271.03xyesRev $18.1B, growth 15% (input: historical growth; tapered), Terminal P/S: 2.9x / 3.5x / 4.1x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$105.001.17xyesEPS $8.75, growth 2% (input: historical EPS growth), PEG=6.84 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$107.041.15xyes√(22.5 × EPS $8.75 × BVPS $58.20) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$282.330.44xyesEPS $8.75 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$328.130.38xyesEPS $8.75 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$94.591.30xyesEPS $8.75 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (buyback)-5.8%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Aflac is a supplemental health and life insurer with most of its business in Japan (58% of the mix) and the rest in the US (42%). Valued the way insurers are, off the return on capital, the price of $115.49 reads as about 2x book, implying a sustained ROE near 13.6% against the roughly 12.4% it has recently earned (and a 16.4% adjusted ROE excluding currency effects in Q1).

The Japan engine reaccelerated in Q1 2026, with sales up 25.5% on new products like the Miraito cancer line and Anshin Palette medical plan, while US pretax adjusted earnings grew modestly. Adjusted EPS rose 5.4% to $1.75, helped by heavy buybacks, though it missed the $1.83 estimate.

The defining variable is the yen. Most of Aflac's earnings and book value originate in yen, so currency translation drives reported results, and the company carries derivative exposure to a sustained weak yen. The price sits below most valuation families, supported by asset and relative-multiple value, with the FX and Japan-margin risk the main offsets.

Bull Case

Lead with where the price sits against the valuation methods, because for Aflac the gap is wide and consistent. At $115.49 the stock trades below the relative-multiple, growth-DCF, and asset-based families: the relative P/E method implies about $176, the perpetual-growth DCF about $190, the two-stage excess-return and residual-income models about $124 to $127, and even the conservative Graham number about $107. The price-to-book frame is the cleanest read for an insurer, and at roughly 2x book the market is assuming a sustained ROE near 13.6%, while Aflac's adjusted return on equity excluding currency remeasurement ran 16.4% in Q1 2026. A business earning a mid-teens core return while the price embeds a lower one is the spread the bull case is built on.

The second pillar is the Japan franchise, which is reaccelerating after years of being viewed as mature. Aflac Japan delivered a 25.5% jump in first-quarter sales, fueled by new products including the Miraito cancer line, the Anshin Palette medical plan, and the Tsumitasu life product. Aflac dominates the third-sector supplemental market in Japan, where its brand and agency distribution are deeply entrenched, and the filing shows the underlying profitability: total benefits and claims fell to 59.3% of premiums from 62.5%, a meaningful improvement in the loss ratio (FY2025 10-K, accession 0001628280-26-011402). Aflac Japan pretax adjusted earnings of $759 million in the quarter dwarf the US segment, and a product-driven sales recovery in the core market is exactly what a mature insurer needs to grow its in-force book.

The third pillar is the capital-return machine, which is among the most reliable in the sector. Aflac returned $1.3 billion to shareholders in Q1 2026, $1.0 billion in buybacks and $315 million in dividends, and raised the dividend 5.2% to $0.61, extending a multi-decade record of increases. Total shareholders' equity climbed to about $30 billion. Buying back a large slug of stock below the valuation families' fair-value estimates is directly accretive to book value per share and to EPS, which is precisely why adjusted EPS rose 5.4% even as adjusted dollar earnings were roughly flat. For a holder, Aflac is a steady, yen-funded compounder that returns excess capital aggressively and trades below where the methods say it should.

Bear Case

Open the bear case with the competitive and structural threats to the Japan franchise, because that is where the durability of the return is decided. Aflac's dominance in Japan's third-sector supplemental insurance is real but contested: domestic giants like Dai-ichi Life and Nippon Life, and bank and digital distribution channels, all compete for the same aging Japanese customer, and Japan's shrinking, aging population is a structural headwind to new-policy growth no matter how good the products are. The 25.5% sales jump is impressive, but it comes off a depressed base and is product-launch driven, the kind of spike that fades once the new lineup is absorbed. Management's own framing, that 2026 sales should be roughly equivalent to 2025, signals that the underlying growth rate is low single digits, not the 25% headline. A franchise defending share in a declining market is working hard to stand still.

The second and more distinctive risk is the yen, which sits underneath every number. The vast majority of Aflac's earnings and book value originate in Japanese yen and must be translated into dollars, so a weaker yen compresses reported dollar EPS and equity even when the underlying Japanese business performs well. FX already shaved $0.02 off adjusted EPS in Q1. More seriously, the company's filing warns that "in a scenario of long-term Japanese yen weakening there could be significant derivative losses that create corresponding liquidity requirements," and that yen investments are "only economically realized, or monetized, through sale, maturity or redemption ... and concurrent conversion to Japanese yen" (FY2025 10-K, accession 0001628280-26-011402). This is a tail risk that ordinary US insurers do not carry: a sustained yen move can create both reported-earnings drag and balance-sheet and liquidity strain through the hedging program.

The third issue is what the conservative methods say once the favorable items are stripped out. The earnings-power value, which capitalizes normalized earnings with no growth, lands near $40 against the $115.49 price (June 27, 2026), and the simple excess-return model lands near $97, below the price. The headline Q1 net income of $1.0 billion was flattered by a swing from prior-year investment losses to investment gains, not by underlying operating growth, and adjusted dollar earnings actually slipped 0.6%. The price sits in the upper half of the peer group's price-to-book, and the inversion notes that only about 65% of firms earning this return sustained it for a decade. The bear case is that the reported strength rests on buybacks, investment gains, and a product-cycle spike, while the underlying franchise grows slowly in a declining market and carries a unique currency exposure, and on a normalized basis the stock is not cheap.

Valuation

Aflac is valued on a financial frame: an insurer is worth the return it earns on its capital, so the price is read off price-to-book. At $115.49 the market is paying about 2x book and assuming a sustained ROE near 13.6%, against a company that has recently earned about 12.4% on a reported basis and 16.4% on an adjusted, currency-excluded basis. The assumed return is within reach of its own record, so the priced-in assumption is characterized as within range, though it sits in the upper half of the peer group's price-to-book.

The insurer-appropriate and growth methods mostly sit above the price, which is what makes the stock look like a value name. The relative P/E lands near $176, the perpetual-growth DCF near $190, the discounted future market cap near $113, and the asset-based two-stage excess-return and residual-income models near $124 to $127. The conservative anchors are lower: the simple excess-return model near $97 and the earnings-power value near $40, the latter reflecting that normalized no-growth earnings support a far lower price. The generic methods that assume a P/S multiple or treat the company like an operating business are not meaningful here and should be set aside.

The practical read is that Aflac is reasonably valued to modestly cheap on its current return, with the answer hinging on two things the price cannot fully see: whether the core ROE holds in the mid-teens and how the yen moves. A reader is underwriting both the durability of the Japan franchise's returns and a stable-to-favorable yen at today's price.

Catalysts

Aflac reported Q1 2026 results in late April 2026 with adjusted EPS of $1.75, up 5.4% on buybacks but a few cents short of the roughly $1.83 estimate, as adjusted dollar earnings were about flat and a weaker yen trimmed $0.02. Net income jumped to $1.0 billion mainly on a swing from prior-year investment losses to gains. Aflac Japan pretax adjusted earnings were $759 million and US earnings $363 million, up about 1.4%. The next quarter is the checkpoint on whether Japan margin and sales momentum hold.

The product catalyst is the Japan lineup. First-quarter Japan sales rose 25.5% on new offerings including the Miraito cancer product, the Anshin Palette medical plan, and the Tsumitasu life product, and management expects full-year 2026 sales roughly in line with 2025. Continued traction in the cancer and medical lines that anchor Aflac's third-sector franchise is the operational catalyst to watch, alongside the loss-ratio improvement that lifted Q1 margins.

The overriding swing factor is currency. Most of Aflac's earnings and book value are yen-denominated, so the yen-dollar rate will determine whether Japan's gains translate cleanly into reported EPS, and a sustained weak-yen scenario carries hedging and liquidity risk. Capital return is the steady catalyst: Aflac returned $1.3 billion in Q1 through buybacks and dividends and raised the dividend 5.2% to $0.61. Analyst sentiment is mixed, with a consensus near Hold and recent targets from Piper Sandler at $130 and Morgan Stanley at $125, modestly above the current price.

Peer Cohorts (Per Segment, With Filing Citations)

Aflac Japan (reported)

Aflac U.S. (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive AFL report on boothcheck